References
- Kuek A, Hazleman BL, AJK Ö. Immune-mediated inflammatory diseases (IMID) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260. doi: 10.1136/pgmj.2006.052688
- El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2–10. doi: 10.3899/jrheum.091461
- NICE. Adalimumab, etanercept, infliximab, and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375). 2021 Jun [cited 2023 Jul 21]. Available from: www.nice.org.uk/guidance/indevelopment/gid-ta10586
- Blandizzi C, Gionchetti P, Armuzzi A, et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014 Jan;27(1 Suppl):1–10. doi: 10.1177/03946320140270S101
- Burisch J, Jess T, Martinato M, et al. ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337. doi: 10.1016/j.crohns.2013.01.010
- Van Nies JA, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(5):861–870. doi: 10.1136/annrheumdis-2012-203130
- Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S154–7.
- AIREF. Gasto hospitalario del Sistema Nacional de Salud: farmacia e inversión en bienes de equipo. Octubre. 2020 [cited 2023 Jul 21]. Available from: https://www.airef.es/wp-content/uploads/2020/10/SANIDAD/PDF-WEB-Gasto-hospitalario-del-SNS.pdf
- Cohen J; Crespo C; Ribera J. Variabilidad en la adopción de biosimilares. Marzo 2020. [cited 2023 Jul 21]. Available from: https://www.biosim.es/informes/variabilidad-en-la-adopcion-de-biosimilares/
- Agencia Europea de Medicamentos y la Comisión Europea. Los biosimilares en la Unión Europea. 2019. [cited 2023 Jul 21]. Available from: https://www.biosim.es/informes/los-biosimilares-en-la-union-europea-guia-informativa-para-profesionales-sanitarios/
- García Goñi M. Análisis de impacto presupuestario de los medicamentos biosimilares en el Sistema Nacional de Salud de España (2009-2022). 2020 Sep [cited 2023 Jul 21]. Available from: https://www.biosim.es/informes/analisis-de-impacto-presupuestario-de-los-medicamentos-biosimilares-en-el-sistema-nacional-de-salud-de-espana-2009-2022/
- The impact of biosimilar competition in Europe. Dic 2020. [cited 2023 Jul 21]. Available from: https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe
- Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. [2019 Mar 28];10:279. doi: 10.3389/fphar.2019.00279
- Lobo F; Del Rio I. Gestión clínica, incentivos y biosimilares. 2020. [cited 2023 Jul 21]. Available from: https://www.biosim.es/informes/gestion-clinica-incentivos-y-biosimilares/
- Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares. Actualización 2018. [cited 2023 Jul 21]. Available from: https://www.ser.es/wp-content/uploads/2018/01/POSICIONAMIENTO-SER-2018.pdf
- de Sanidad M. Consumo y Bienestar Social (septiembre 2019). Plan de acción para fomentar la utilización de medicamentos reguladores del mercado en el SNS: Medicamentos biosimilares y medicamentos genéricos. Available at. [cited 2023 Jul 21]. Available from: https://www.mscbs.gob.es/profesionales/farmacia/pdf/PlanAccionSNSmedicamentosReguladoresMercado.pdf
- Smolen JS, Caporali R, Doerner T, et al. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. RMD Open. 2021 Jun;7(2):e001637. doi: 10.1136/rmdopen-2021-001637
- Documento de posicionamiento de la Sociedad Española de Farmacia Hospitalaria sobre medicamentos biosimilares. 17 de octubre de 2017. Available at cited 2023 Jul 21]. Available from: https://www.sefh.es/sefhpdfs/PosicionamientoBiosimilaresSEFH_documentocompleto_Definitivo.pdf
- Anisdahl K, Svatun Lirhus S, Medhus AW, et al. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study. Scand J Gastroenterol. 2021 Oct;56(10):1163–1168. doi: 10.1080/00365521.2021.1955147
- Avouac J, Moltó A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018 Apr;47(5):741–748. doi: 10.1016/j.semarthrit.2017.10.002
- Ascef BO, Almeida MO, de Medeiros Ribeiro AC, et al. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis. Syst Rev. [2021 Jul 17];10(1):205. doi: 10.1186/s13643-021-01754-x
- Müskens WD, Rongen-van Dartel SAA, Adang EMM, et al. Biosimilars in the management of chronic inflammatory diseases: the Dutch experience. Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):76–81. doi: 10.31138/mjr.30.1.76
- EMA/627319/2022. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023 abr 21 [cited 2023 Jul 24]. Available from: https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf